Literature DB >> 17885736

Mathematical modeling of topotecan pharmacokinetics and toxicodynamics in mice.

Jin Chen1, Qiang Lu, Joseph P Balthasar.   

Abstract

The objective of this study was to investigate the pharmacokinetics and toxicodynamics of topotecan (TPT) in mice and to develop an integrated pharmacokinetic/toxicodynamic (PK/TD) model to characterize the relationship between the time course of TPT disposition and the time course of TPT-induced toxicity. TPT was administered to groups of 3-5 mice via i.v. bolus injection, i.p. bolus injection, and by i.p. infusion over 24, 72 and 168 h. Body weight was monitored to assess TPT-induced toxicity, and serial blood samples were collected and analyzed via HPLC to assess TPT pharmacokinetics. We found that TPT-induced toxicity increased dose-dependently for each mode of dosing investigated. The time course of topotecan-induced body weight-loss was delayed relative to the time course of topotecan disposition; nadir body weight was observed as late as 6 days following i.p. bolus dosing, and 3-5 days following termination of i.p. infusion. TPT exhibited non-linear disposition, which was well-characterized through the use of a two-compartment model with saturable elimination from the central compartment. Toxicodynamic data were characterized with an integrated PK/TD model that incorporated an indirect-effect model and four transit compartments to describe transduction events associated with TPT-induced toxicity. This model will be used to support the development of an inverse-targeting strategy that aims to enhance topotecan safety and efficacy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17885736     DOI: 10.1007/s10928-007-9072-2

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.410


  47 in total

1.  Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study.

Authors:  D G Tubergen; C F Stewart; C B Pratt; W C Zamboni; N Winick; V M Santana; Z A Dryer; J Kurtzberg; B Bell; H Grier; T J Vietti
Journal:  J Pediatr Hematol Oncol       Date:  1996-11       Impact factor: 1.289

2.  Physiologic indirect response models characterize diverse types of pharmacodynamic effects.

Authors:  W J Jusko; H C Ko
Journal:  Clin Pharmacol Ther       Date:  1994-10       Impact factor: 6.875

3.  Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer.

Authors:  L B Grochow; E K Rowinsky; R Johnson; S Ludeman; S H Kaufmann; F L McCabe; B R Smith; L Hurowitz; A DeLisa; R C Donehower
Journal:  Drug Metab Dispos       Date:  1992 Sep-Oct       Impact factor: 3.922

Review 4.  Clinical pharmacokinetics of topotecan.

Authors:  V M Herben; W W ten Bokkel Huinink; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

Review 5.  Animal models for studying the action of topoisomerase I targeted drugs.

Authors:  J Thompson; C F Stewart; P J Houghton
Journal:  Biochim Biophys Acta       Date:  1998-10-01

6.  Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.

Authors:  L J van Warmerdam; W W ten Bokkel Huinink; S Rodenhuis; I Koier; B E Davies; H Rosing; R A Maes; J H Beijnen
Journal:  J Clin Oncol       Date:  1995-07       Impact factor: 44.544

7.  O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan.

Authors:  H Rosing; D M van Zomeren; E Doyle; A Bult; J H Beijnen
Journal:  Anticancer Drugs       Date:  1998-08       Impact factor: 2.248

8.  Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer.

Authors:  V M Herben; W W ten Bokkel Huinink; M E Schot; I Hudson; J H Beijnen
Journal:  Anticancer Drugs       Date:  1998-06       Impact factor: 2.248

9.  Intratibial injection of an anti-doxorubicin monoclonal antibody prevents drug-induced myelotoxicity in mice.

Authors:  D Morelli; S Ménard; S Cazzaniga; M I Colnaghi; A Balsari
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice.

Authors:  Z M Prijovich; B-M Chen; Y-L Leu; J-W Chern; S R Roffler
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

View more
  6 in total

1.  Investigation of the influence of nephropathy on monoclonal antibody disposition: a pharmacokinetic study in a mouse model of diabetic nephropathy.

Authors:  Frank A Engler; Bo Zheng; Joseph P Balthasar
Journal:  Pharm Res       Date:  2013-11-08       Impact factor: 4.200

2.  PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice.

Authors:  Dhaval K Shah; Joseph P Balthasar
Journal:  Int J Pharm       Date:  2014-02-06       Impact factor: 5.875

3.  Population Pharmacokinetic-Pharmacodynamic Modeling of 5-Fluorouracil for Toxicities in Rats.

Authors:  Shinji Kobuchi; Yukako Ito; Toshiyuki Sakaeda
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-08       Impact factor: 2.441

4.  Physiologically based pharmacokinetic model for topotecan in mice.

Authors:  Dhaval K Shah; Joseph P Balthasar
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-11-20       Impact factor: 2.745

5.  Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy.

Authors:  Dhaval K Shah; Beom Soo Shin; Jean Veith; Karoly Tóth; Ralph J Bernacki; Joseph P Balthasar
Journal:  J Pharmacol Exp Ther       Date:  2009-02-20       Impact factor: 4.030

6.  Semi-Mechanism-Based Pharmacokinetic-Toxicodynamic Model of Oxaliplatin-Induced Acute and Chronic Neuropathy.

Authors:  Shinji Kobuchi; Risa Shimizu; And Yukako Ito
Journal:  Pharmaceutics       Date:  2020-02-03       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.